175 related articles for article (PubMed ID: 34587431)
1. MMP-16 as a New Biomarker for Predicting Prognosis and Chemosensitivity of Serous Ovarian Cancer: A Study Based on Bioinformatics Analysis.
Wang W; Liu Y; Yang Y; Huang X; Hou Y
Crit Rev Eukaryot Gene Expr; 2021; 31(4):1-8. PubMed ID: 34587431
[TBL] [Abstract][Full Text] [Related]
2. [Identification and prognostic value of differentially expressed proteins of patients with platinum resistance epithelial ovarian cancer in serum].
Wu WJ; Wang Q; Zhang W; Li L
Zhonghua Fu Chan Ke Za Zhi; 2016 Jul; 51(7):515-23. PubMed ID: 27465871
[TBL] [Abstract][Full Text] [Related]
3. The NER-related gene GTF2H5 predicts survival in high-grade serous ovarian cancer patients.
Gayarre J; Kamieniak MM; Cazorla-Jiménez A; Muñoz-Repeto I; Borrego S; García-Donas J; Hernando S; Robles-Díaz L; García-Bueno JM; Ramón Y Cajal T; Hernández-Agudo E; Heredia Soto V; Márquez-Rodas I; Echarri MJ; Lacambra-Calvet C; Sáez R; Cusidó M; Redondo A; Paz-Ares L; Hardisson D; Mendiola M; Palacios J; Benítez J; García MJ
J Gynecol Oncol; 2016 Jan; 27(1):e7. PubMed ID: 26463438
[TBL] [Abstract][Full Text] [Related]
4. Engrailed-2 (EN2) - a novel biomarker in epithelial ovarian cancer.
McGrath SE; Annels N; Madhuri TK; Tailor A; Butler-Manuel SA; Morgan R; Pandha H; Michael A
BMC Cancer; 2018 Oct; 18(1):943. PubMed ID: 30285763
[TBL] [Abstract][Full Text] [Related]
5. Prognostic Role of Zinc Finger Homeobox 4 in Ovarian Serous Cystadenocarcinoma.
Ha M; Kim J; Park SM; Hong CM; Han ME; Song P; Kang CD; Lee D; Kim YH; Hur J; Oh SO
Genet Test Mol Biomarkers; 2020 Mar; 24(3):145-149. PubMed ID: 32105524
[No Abstract] [Full Text] [Related]
6. Prognostic Significance of Increased Expression of Annexin A10 (ANXA10) in Serous Epithelial Ovarian Cancer.
Wang J; Zhao S; Wang F; Wang J; Zhang Y
Med Sci Monit; 2019 Jul; 25():5666-5673. PubMed ID: 31363077
[TBL] [Abstract][Full Text] [Related]
7. Over-expression of Sirt1 contributes to chemoresistance and indicates poor prognosis in serous epithelial ovarian cancer (EOC).
Shuang T; Wang M; Zhou Y; Shi C
Med Oncol; 2015 Dec; 32(12):260. PubMed ID: 26520143
[TBL] [Abstract][Full Text] [Related]
8. Low expression of NCALD is associated with chemotherapy resistance and poor prognosis in epithelial ovarian cancer.
Feng LY; Li L
J Ovarian Res; 2020 Mar; 13(1):35. PubMed ID: 32228639
[TBL] [Abstract][Full Text] [Related]
9. Overexpression of the recently identified oncogene REDD1 correlates with tumor progression and is an independent unfavorable prognostic factor for ovarian carcinoma.
Chang B; Meng J; Zhu H; Du X; Sun L; Wang L; Li S; Yang G
Diagn Pathol; 2018 Nov; 13(1):87. PubMed ID: 30428884
[TBL] [Abstract][Full Text] [Related]
10. A DNA repair pathway-focused score for prediction of outcomes in ovarian cancer treated with platinum-based chemotherapy.
Kang J; D'Andrea AD; Kozono D
J Natl Cancer Inst; 2012 May; 104(9):670-81. PubMed ID: 22505474
[TBL] [Abstract][Full Text] [Related]
11. Integrin Subunit beta 8 (ITGB8) Upregulation Is an Independent Predictor of Unfavorable Survival of High-Grade Serous Ovarian Carcinoma Patients.
He J; Liu Y; Zhang L; Zhang H
Med Sci Monit; 2018 Dec; 24():8933-8940. PubMed ID: 30531684
[TBL] [Abstract][Full Text] [Related]
12. Annexin A8 can serve as potential prognostic biomarker and therapeutic target for ovarian cancer: based on the comprehensive analysis of Annexins.
Gou R; Zhu L; Zheng M; Guo Q; Hu Y; Li X; Liu J; Lin B
J Transl Med; 2019 Sep; 17(1):275. PubMed ID: 31474227
[TBL] [Abstract][Full Text] [Related]
13. PD-L1 expression on stromal tumor-infiltrating lymphocytes is a favorable prognostic factor in ovarian serous carcinoma.
Kim KH; Choi KU; Kim A; Lee SJ; Lee JH; Suh DS; Kwon BS; Hwang C
J Ovarian Res; 2019 Jun; 12(1):56. PubMed ID: 31208449
[TBL] [Abstract][Full Text] [Related]
14. Clinicopathological and prognostic significance of caveolin-1 and ATG4C expression in the epithelial ovarian cancer.
Zeng Y; Chen M; Ganesh S; Hu S; Chen H
PLoS One; 2020; 15(5):e0232235. PubMed ID: 32401768
[TBL] [Abstract][Full Text] [Related]
15. Optimal cutoff age for predicting prognosis associated with serous epithelial ovarian cancer: what is the best age cutoff?
Kim J; Chang Y; Kim TJ; Lee JW; Kim BG; Bae DS; Choi CH
J Gynecol Oncol; 2019 Jan; 30(1):e11. PubMed ID: 30479095
[TBL] [Abstract][Full Text] [Related]
16. FOXM1 expression is significantly associated with chemotherapy resistance and adverse prognosis in non-serous epithelial ovarian cancer patients.
Tassi RA; Todeschini P; Siegel ER; Calza S; Cappella P; Ardighieri L; Cadei M; Bugatti M; Romani C; Bandiera E; Zanotti L; Tassone L; Guarino D; Santonocito C; Capoluongo ED; Beltrame L; Erba E; Marchini S; D'Incalci M; Donzelli C; Santin AD; Pecorelli S; Sartori E; Bignotti E; Odicino F; Ravaggi A
J Exp Clin Cancer Res; 2017 May; 36(1):63. PubMed ID: 28482906
[TBL] [Abstract][Full Text] [Related]
17. Elevated preoperative plasma D-dimer level is a useful predictor of chemoresistance and poor disease outcome for serous ovarian cancer patients.
Liu P; Wang Y; Tong L; Xu Y; Zhang W; Guo Z; Ni H
Cancer Chemother Pharmacol; 2015 Dec; 76(6):1163-71. PubMed ID: 26542279
[TBL] [Abstract][Full Text] [Related]
18. The down-regulation of long non-coding RNA LINC01088 is associated with the poor prognosis of epithelial ovarian cancer patients.
Ai H; Xie W; Xiu AH; Li N; Zhang ST; Zhang YL; Xue XO
Eur Rev Med Pharmacol Sci; 2018 Sep; 22(18):5836-5841. PubMed ID: 30280763
[TBL] [Abstract][Full Text] [Related]
19. Diagnostic and prognostic values of MMP-9 expression in ovarian cancer: A study based on bioinformatics analysis and meta-analysis.
Liu C; Shen Y; Tan Q
Int J Biol Markers; 2023 Mar; 38(1):15-24. PubMed ID: 36448239
[TBL] [Abstract][Full Text] [Related]
20. HOXA4/HOXB3 gene expression signature as a biomarker of recurrence in patients with high-grade serous ovarian cancer following primary cytoreductive surgery and first-line adjuvant chemotherapy.
Miller KR; Patel JN; Zhang Q; Norris EJ; Symanowski J; Michener C; Sehouli J; Braicu I; Destephanis DD; Sutker AP; Jones W; Livasy CA; Biscotti C; Ganapathi RN; Tait DL; Ganapathi MK
Gynecol Oncol; 2018 Apr; 149(1):155-162. PubMed ID: 29402501
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]